Exchange: NASDAQ·Updated 08:57 AM EDT
ABVC logo

ABVC ABVC BioPharma Inc

$1.03
$0.03
(3.00%)
Pre-Market
Prev Close $1.00
Mkt Cap$26.65M
Vol2,345.00

About ABVC

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
40

Bearish Sentiment

How do you feel about ABVC?

Advertisement|Remove ads.